Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles.

[1]  I. Bernstein,et al.  Correlates of self-reported quality of life in adults and children with morphea. , 2014, Journal of the American Academy of Dermatology.

[2]  E. Ferrannini,et al.  Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. , 2014, Autoimmunity reviews.

[3]  J. Ho,et al.  Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma , 2013, Arthritis Research & Therapy.

[4]  K. Torok,et al.  The Localized Scleroderma Cutaneous Assessment Tool: responsiveness to change in a pediatric clinical population. , 2013, Journal of the American Academy of Dermatology.

[5]  O Abbas,et al.  Clinicopathological study of 81 cases of localized and systemic scleroderma , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  M. Molińska-Glura,et al.  Interleukin-17A and interleukin-23 in morphea , 2012, Archives of medical science : AMS.

[7]  M. Hasegawa,et al.  Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines. , 2012, Seminars in arthritis and rheumatism.

[8]  M. Molińska-Glura,et al.  Clinical immunology Interleukin 1β in morphea , 2012 .

[9]  Mara Becker,et al.  Development of consensus treatment plans for juvenile localized scleroderma: A roadmap toward comparative effectiveness studies in juvenile localized scleroderma , 2012, Arthritis care & research.

[10]  J. Baraut,et al.  Les cytokines dans la sclérodermie systémique , 2012 .

[11]  T. Arkachaisri,et al.  Methotrexate and Corticosteroids in the Treatment of Localized Scleroderma: A Standardized Prospective Longitudinal Single-center Study , 2012, The Journal of Rheumatology.

[12]  K. Torok,et al.  Cytokine profiles in localized scleroderma and relationship to clinical features. , 2011, Cytokine.

[13]  M. Cutrone,et al.  Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. , 2011, Arthritis and rheumatism.

[14]  L. Michel,et al.  Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. , 2010, Autoimmunity reviews.

[15]  P. Tak,et al.  Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis , 2010, Science Translational Medicine.

[16]  C. Magro,et al.  Treatment of recalcitrant generalized morphea with infliximab. , 2010, Archives of dermatology.

[17]  T. Medsger,et al.  Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study. , 2010, Rheumatology.

[18]  T. Medsger,et al.  The Localized Scleroderma Skin Severity Index and Physician Global Assessment of Disease Activity: A Work in Progress Toward Development of Localized Scleroderma Outcome Measures , 2009, The Journal of Rheumatology.

[19]  M. Mayes,et al.  Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations , 2009, Arthritis research & therapy.

[20]  T. Medsger,et al.  Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. , 2009, Arthritis and rheumatism.

[21]  T. Medsger,et al.  Serum Autoantibodies and Their Clinical Associations in Patients with Childhood- and Adult-Onset Linear Scleroderma. A Single-Center Study , 2008, The Journal of Rheumatology.

[22]  A. Paller,et al.  Pediatric morphea (localized scleroderma): review of 136 patients. , 2008, Journal of the American Academy of Dermatology.

[23]  F. Zulian.  New developments in localized scleroderma , 2008, Current opinion in rheumatology.

[24]  M. Aurrand-Lions,et al.  Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. , 2007, Arthritis and rheumatism.

[25]  P. Woo,et al.  Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. , 2006, Rheumatology.

[26]  T. Gambichler,et al.  Clinical and serological characteristics of progressive facial hemiatrophy: a case series of 12 patients. , 2006, Journal of the American Academy of Dermatology.

[27]  T. Matsushita,et al.  Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. , 2006, The Journal of rheumatology.

[28]  Guangwu Xu,et al.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know , 2006, Cell Research.

[29]  C. Wouters,et al.  Localized scleroderma in childhood is not just a skin disease. , 2005, Arthritis and rheumatism.

[30]  L. Settas,et al.  Early T cell activation in the skin from patients with systemic sclerosis , 2005, Annals of the rheumatic diseases.

[31]  K. Takehara,et al.  Localized scleroderma is an autoimmune disorder. , 2005, Rheumatology.

[32]  T. Wynn.  Fibrotic disease and the TH1/TH2 paradigm , 2004, Nature Reviews Immunology.

[33]  M. Fujimoto,et al.  Serum Levels of Tumor Necrosis Factor and Interleukin-13 Are Elevated in Patients with Localized Scleroderma , 2003, Dermatology.

[34]  A. Parodi,et al.  Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases. , 2003, European journal of dermatology : EJD.

[35]  K. Esposito,et al.  Peripheral Blood T Lymphocytes from Systemic Sclerosis Patients Show Both Th1 and Th2 Activation , 2001, Journal of Clinical Immunology.

[36]  A. Giannetti,et al.  Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. , 2001, The Journal of allergy and clinical immunology.

[37]  K. Takabayashi,et al.  Increased interleukin-17 production in patients with systemic sclerosis. , 2000, Arthritis and rheumatism.

[38]  R. Wise,et al.  Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. , 1999, Arthritis and rheumatism.

[39]  J. Sánchez,et al.  Histopathologic differentiation between localized and systemic scleroderma. , 1998, The American Journal of dermatopathology.

[40]  M. Fujimoto,et al.  Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. , 1997, The Journal of rheumatology.

[41]  C. Clavel,et al.  Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. , 1996, Archives of dermatology.

[42]  A Y Finlay,et al.  The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use , 1995, The British journal of dermatology.

[43]  M. Fujimoto,et al.  Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma , 1995, Archives of Dermatological Research.

[44]  M. Fujimoto,et al.  Demonstration of interleukin 8 in serum samples of patients with localized scleroderma. , 1994, Archives of dermatology.

[45]  T. Medsger,et al.  Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities. , 1986, Annals of internal medicine.

[46]  T. Whiteside,et al.  Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. , 1984, Arthritis and rheumatism.

[47]  E. Keystone,et al.  Immunoregulatory T cell subpopulations in patients with scleroderma using monoclonal antibodies. , 1982, Clinical and experimental immunology.

[48]  T. Whiteside,et al.  Abnormalities of T lymphocyte subsets in patients with progressive systemic sclerosis (PSS, scleroderma). , 1981, The Journal of laboratory and clinical medicine.

[49]  M. Mayes,et al.  Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis. , 2013, Arthritis and rheumatism.

[50]  L. Michel,et al.  [Cytokines in systemic sclerosis]. , 2012, Pathologie-biologie.

[51]  T. Wynn.  Fibrotic disease and the T(H)1/T(H)2 paradigm. , 2004, Nature reviews. Immunology.

[52]  S. Gabriel,et al.  The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. , 1997, The Journal of rheumatology.

[53]  F. Wigley,et al.  Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. , 1992, Arthritis and rheumatism.

[54]  F. Wigley,et al.  Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. , 1992, Arthritis and rheumatism.